Immunome (IMNM) Net Cash Flow (2019 - 2026)

Immunome (IMNM) has 8 years of Net Cash Flow data on file, last reported at -$70.8 million in Q1 2026.

• Quarterly Net Cash Flow fell 161.95% year-over-year to -$70.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $325.2 million (up 2785.3% YoY) and the FY2025 annual result came in at $510.2 million, up 1042.19% from the prior year.
• Net Cash Flow declined to -$70.8 million in Q1 2026, from $380.8 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $380.8 million in Q4 2025 to a low of -$113.6 million in Q2 2025.
• A 5-year average of $31.4 million and a median of -$6.4 million in 2022 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2024 — Net Cash Flow slumped 1637.53% — and 2025, when it soared 3217.32%.
• Tracing IMNM's Net Cash Flow over 5 years: stood at -$6.8 million in 2022, then soared by 218.99% to $8.0 million in 2023, then tumbled by 251.99% to -$12.2 million in 2024, then soared by 3217.32% to $380.8 million in 2025, then sank by 118.59% to -$70.8 million in 2026.
• The last three Net Cash Flow figures came in at -$70.8 million (Q1 2026), $380.8 million (Q4 2025), and $128.8 million (Q3 2025), per Business Quant data.